Skip to content
Login
Insights
All Insights
In My Opinion
In Your Practice
Patient Populations
News
All News
Recent Updates
FDA Approvals
Clinical Trials
Conference Correspondent
Explore by Topic
All Topics
Cancer Types
Therapeutic Approaches
Diagnostics & Biomarkers
Multimedia
All Media
Videos
Podcasts
Sign Up
Already a member?
Log In
Insights
All Insights
In My Opinion
In Your Practice
Patient Populations
News
All News
Recent Updates
FDA Approvals
Clinical Trials
Conference Correspondent
Explore by Topic
All Topics
Cancer Types
Therapeutic Approaches
Diagnostics & Biomarkers
Multimedia
All Media
Videos
Podcasts
Sign Up
Already a member?
Log In
Login
Log In
Account Settings
Login
Log In
Account Settings
Login
Sign Up
Real Clinics. Real Patients. Real Oncology.
Home
/
Topics
/
Cancer Types
/
Solid Tumors
Home /
Solid Tumors
Solid Tumors
Solid Tumors
FDA Approvals
Tucatinib Plus Trastuzumab and Pertuzumab Has Been Approved for the Maintenance Treatment of HER2-Positive Breast Cancer
October 7, 2026
Clinical Trials
Early COMPPARE Results Show Similar Patient-Reported Outcomes With Proton Therapy and IMRT in Prostate Cancer
October 1, 2026
Clinical Trials
TALAPRO-3: Talazoparib Plus Enzalutamide Delays Progression in HRR-Altered mCSPC
October 1, 2026
Recent Updates
Perioperative Apalutamide Plus ADT Improves Pathologic Response and Delays Metastasis in High-Risk Prostate Cancer: PROTEUS Final Analysis
October 1, 2026
Clinical Trials
AcTION Phase 1 Trial Shows Strong Early Activity and Favorable Safety in mCRPC
October 1, 2026
FDA Approvals
ETCAMAH Approval Marks a New, Earlier Line of Attack Against Endocrine-Resistant Breast Cancer
September 24, 2026
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
Recent Updates
Advanced Treatment Available For Cancer Patients In Southern W.Va.
September 2, 2026
Patient Populations
High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
Neil M. Iyengar
, MD;
Annalise Labatut
, PharmD, BCOP
August 26, 2026
Recent Updates
KU Cancer Researchers Aim to Expand Horizons of CAR T-Cell Treatment
August 26, 2026
FDA Approvals
Tucatinib Plus Trastuzumab and Pertuzumab Has Been Approved for the Maintenance Treatment of HER2-Positive Breast Cancer
October 7, 2026
Clinical Trials
Early COMPPARE Results Show Similar Patient-Reported Outcomes With Proton Therapy and IMRT in Prostate Cancer
October 1, 2026
Clinical Trials
TALAPRO-3: Talazoparib Plus Enzalutamide Delays Progression in HRR-Altered mCSPC
October 1, 2026
Recent Updates
Perioperative Apalutamide Plus ADT Improves Pathologic Response and Delays Metastasis in High-Risk Prostate Cancer: PROTEUS Final Analysis
October 1, 2026
Clinical Trials
AcTION Phase 1 Trial Shows Strong Early Activity and Favorable Safety in mCRPC
October 1, 2026
FDA Approvals
ETCAMAH Approval Marks a New, Earlier Line of Attack Against Endocrine-Resistant Breast Cancer
September 24, 2026
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
Recent Updates
Advanced Treatment Available For Cancer Patients In Southern W.Va.
September 2, 2026
Patient Populations
High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
Neil M. Iyengar
, MD;
Annalise Labatut
, PharmD, BCOP
August 26, 2026
Recent Updates
KU Cancer Researchers Aim to Expand Horizons of CAR T-Cell Treatment
August 26, 2026
News & Insights
FDA Approvals
Tucatinib Plus Trastuzumab and Pertuzumab Has Been Approved for the Maintenance Treatment of HER2-Positive Breast Cancer
October 7, 2026
Clinical Trials
Early COMPPARE Results Show Similar Patient-Reported Outcomes With Proton Therapy and IMRT in Prostate Cancer
October 1, 2026
Clinical Trials
TALAPRO-3: Talazoparib Plus Enzalutamide Delays Progression in HRR-Altered mCSPC
October 1, 2026
Recent Updates
Perioperative Apalutamide Plus ADT Improves Pathologic Response and Delays Metastasis in High-Risk Prostate Cancer: PROTEUS Final Analysis
October 1, 2026
Clinical Trials
AcTION Phase 1 Trial Shows Strong Early Activity and Favorable Safety in mCRPC
October 1, 2026
FDA Approvals
ETCAMAH Approval Marks a New, Earlier Line of Attack Against Endocrine-Resistant Breast Cancer
September 24, 2026
Clinical Trials
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
Samantha Hodges
, PharmD;
Katelyn Patterson
, PharmD, et al.
September 8, 2026
Recent Updates
Advanced Treatment Available For Cancer Patients In Southern W.Va.
September 2, 2026
Patient Populations
High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer
Neil M. Iyengar
, MD;
Annalise Labatut
, PharmD, BCOP
August 26, 2026
Podcasts
No results were found
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastrointestinal Cancers
Head and Neck Cancer
Lung Cancer
Prostate Cancer
What are you looking for?
Search
Search
POPULAR SEARCHES
Adjuvant Therapy
ASCO 2026
Biomarker Testing
Bladder Cancer
